# Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

> **NCT03587844** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 58 (estimated)

## Conditions studied

- Mycosis Fungoides
- Lymphomatoid Papulosis
- Sezary Syndrome

## Interventions

- **DRUG:** brentuximab vedotin
- **DRUG:** brentuximab vedotin
- **DRUG:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT03587844
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-07-03
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03587844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03587844, "Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03587844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*